Financial Statements

Financial Statements

Unaudited Condensed Consolidated Interim Financial Statements for the First Six Months of 2026

Consolidated Statement of Income and Comprehensive Income/Loss (–) (unaudited)

Consolidated income statement

	Six months ended June 30	
(thousands of €, except per share data)	**2026**	2025
Supply revenues	14,049	18,486
Collaboration revenues	4,542	121,779
Total net revenues	**18,591**	**140,265**
Cost of sales	(13,944)	(18,435)
Research and development expenses	(56,486)	(278,027)
Sales and marketing expenses	(5,826)	(1,556)
General and administrative expenses	(52,184)	(72,914)
Other operating income	2,635	14,932
Operating loss	**(107,214)**	**(215,735)**
Fair value adjustments and net currency exchange differences	97,119	(66,228)
Other financial income	26,479	22,536
Other financial expenses	(414)	(1,364)
Profit/loss (–) before tax	**15,970**	**(260,791)**
Income taxes	(140)	1,788
Net profit/loss (–) from continuing operations	**15,830**	**(259,003)**
Net profit/loss (–) from discontinued operations, net of tax	**771**	**(148)**
Net profit/loss (–)	**16,601**	**(259,151)**

(thousands of €, except per share data)	Six months ended June 30 2026	2025
Net profit/loss (–) attributable to:		
Owners of the parent	16,601	(259,151)
Basic and diluted earnings/loss (–) per share	**0.25**	**(3.93)**
Basic and diluted earnings/loss (–) per share from continuing operations	**0.24**	**(3.93)**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Consolidated statement of comprehensive income/loss (–)

(thousands of €)	Six months ended June 30 2026	2025
Net profit/loss (–)	**16,601**	**(259,151)**
Items that will not be reclassified subsequently to profit or loss:		
Fair value adjustment financial assets held at fair value through other comprehensive income	469	(6,012)
Items that may be reclassified subsequently to profit or loss:		
Translation differences, arisen from translating foreign activities	9,990	(618)
Other comprehensive income/loss (–), net of income tax	**10,459**	**(6,630)**
Total comprehensive income/loss (–) attributable to:		
Owners of the parent	27,060	(265,781)
Total comprehensive income/loss (–) attributable to owners of the parent arises from:		
Continuing operations	26,289	(265,633)
Discontinued operations	771	(148)
Total comprehensive income/loss (–), net of income tax	**27,060**	**(265,781)**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Consolidated Statement of Financial Position (unaudited)

(thousands of €)	June 30 **2026**	December 31 2025
Assets		
Intangible assets	750,659	848
Property, plant and equipment	76,885	80,663
Deferred tax assets	134	195
Non-current R&D incentives receivables	93,112	126,662
Non-current contingent consideration receivable	44,441	47,750
Equity investments	73,857	46,809
Other non-current assets	2,677	2,959
Convertible loan	62	21,175
Non-current assets	**1,041,827**	**327,061**
Inventories	8,544	22,493
Trade and other receivables	23,695	20,706
Current R&D incentives receivables	32,601	31,208
Current financial investments	2,103,597	2,910,180
Cash and cash equivalents	135,952	87,868
Other current assets	3,963	7,002
Current assets from continuing operations	**2,308,352**	**3,079,457**
Assets in disposal group classified as held for sale	**1,009**	**–**
Total current assets	**2,309,361**	**3,079,457**
Total assets	**3,351,188**	**3,406,518**

(thousands of €)	June 30 **2026**	December 31 2025
Equity and liabilities		
Share capital	293,937	293,937
Share premium account	2,736,994	2,736,994
Other reserves	(8,168)	(8,637)
Translation differences	12,987	2,997
Own shares	(6,078)	–
Accumulated result	233,958	210,577
Total equity	**3,263,630**	**3,235,868**
Non-current lease liabilities	4,773	5,186
Other non-current liabilities	12,461	12,601
Non-current liabilities	**17,234**	**17,787**
Current lease liabilities	1,589	1,729
Trade and other liabilities	66,347	104,647
Provisions	1,402	45,499
Current tax payable	953	956
Current deferred income	33	32
Total current liabilities	**70,324**	**152,863**
Total liabilities	**87,558**	**170,650**
Total equity and liabilities	**3,351,188**	**3,406,518**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Consolidated Cash Flow Statement (unaudited)

(thousands of €)	Six months ended June 30 2026	2025
Net profit/loss (–) of the period	**16,601**	**(259,151)**
Decrease (–)/increase in provisions	(44,100)	36,868
Adjustment for other non-cash transactions	(84,749)	131,337
Adjustment for items to disclose separately under operating cash flow	(24,186)	(22,743)
Adjustment for items to disclose under investing and financing cash flows	(6,484)	(41,328)
Change in working capital other than deferred income	1,136	112,335
Cash used for other liabilities related to the acquisition of subsidiaries	–	(1,792)
Decrease in deferred income	–	(117,286)
Cash used in operations	**(141,782)**	**(161,760)**
Interest paid	(127)	(304)
Interest received	25,855	14,880
Corporate taxes paid	(787)	(204)
Net cash flow used in operating activities	**(116,841)**	**(147,388)**
Purchase of property, plant and equipment	(152)	(9,250)
Purchase of intangible fixed assets	–	(155)
Proceeds from disposal of property, plant and equipment	2,399	–
Purchase of financial investments	(902,036)	(2,087,499)
Investment income received related to financial investments	52,555	42,338
Sale of financial investments	1,740,650	2,201,540
Proceeds from settlement of hedging instrument	–	22,745
Cash in from the disposal of subsidiaries, net of cash disposed of	4,112	9,733
Convertible loan issued to third party	(62)	(20,000)
Acquisition of equity investments held at fair value through other comprehensive income	(1,031)	–
Cash out from acquisition of subsidiaries, net of cash acquired	(733,521)	–
Net cash flow generated from investing activities	**162,914**	**159,452**
Payment of lease liabilities	(1,578)	(1,611)
Purchase of own shares	(2,870)	–
Net cash flow used in financing activities	**(4,448)**	**(1,611)**
Increase in cash and cash equivalents	**41,625**	**10,453**

(thousands of €)	Six months ended June 30 2026	2025
Cash and cash equivalents at beginning of the period	**87,868**	**64,239**
Increase in cash and cash equivalents	41,625	10,453
Effect of exchange rate differences on cash and cash equivalents	6,459	(3,023)
Cash and cash equivalents at end of the period	**135,952**	**71,669**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Consolidated Statement of Changes in Equity (unaudited)

(thousands of €)	Share capital	Share premium account	Own shares	Translation differences	Other reserves	Accumul. result	**Total**
On January 1, 2025	**293,937**	**2,736,994**	**–**	**3,472**	**(3,158)**	**(134,306)**	**2,896,939**
Net loss						(259,151)	(259,151)
Other comprehensive loss				(573)	(6,057)		(6,630)
Total comprehensive loss				**(573)**	**(6,057)**	**(259,151)**	**(265,781)**
Share-based compensation						12,661	12,661
On June 30, 2025	**293,937**	**2,736,994**	**–**	**2,899**	**(9,215)**	**(380,796)**	**2,643,819**
On January 1, 2026	**293,937**	**2,736,994**	**–**	**2,997**	**(8,637)**	**210,577**	**3,235,868**
Net profit						16,601	16,601
Other comprehensive income				9,990	469		10,459
Total comprehensive income				**9,990**	**469**	**16,601**	**27,060**
Purchase of own shares			(6,078)				(6,078)
Share-based compensation						6,780	6,780
On June 30, 2026	**293,937**	**2,736,994**	**(6,078)**	**12,987**	**(8,168)**	**233,958**	**3,263,630**

The accompanying **notes** form an integral part of these condensed consolidated financial statements.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements for the First Six Months of 2026

Basis of Preparation

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 'Interim Financial Reporting' as adopted by the European Union. The condensed consolidated interim financial statements do not contain all information required for an annual report and should therefore be read in conjunction with our **Annual Report 2025**.

Material Accounting Policies

There were no significant changes in accounting policies applied by us in these condensed consolidated interim financial statements compared to those used in the most recent annual consolidated financial statements of December 31, 2025.

New standards and interpretations applicable for the annual period beginning on January 1, 2026 did not have any material impact on our condensed consolidated interim financial statements.

We have not early adopted any other standard, interpretation, or amendment that has been issued but is not yet effective. We are currently still assessing the impact of these new accounting standards and amendments that are not yet effective, but we expect no standard to have a material impact on our financial statements in the period of initial application except for the effect of IFRS 18 (effective for the period beginning January 1, 2027). We refer to our **Annual Report 2025** for more detailed information.

Summary of Significant Transactions

Acquisition of Ouro Medicines and collaboration with Gilead Sciences, Inc. ("Gilead")

Framework Agreement with Gilead

On March 23, 2026, Gilead announced that it had entered into a definitive agreement to acquire all of the outstanding equity interests of Ouro Medicines Inc. ("Ouro" or "Ouro Medicines") for a total upfront cash consideration of $1.675 billion, subject to customary adjustments, and up to $500 million in contingent milestone payments (the "Acquisition"). In connection with the Acquisition, we have entered into a Framework Agreement with Gilead, which comprises the following components:

i. relief under the Option, License and Collaboration Agreement dated July 14, 2019 between Gilead and us (the "OLCA"), to enable us to deploy at least $500 million of our available cash independently from Gilead and outside the scope of the OLCA and the Ouro transaction, including up to $150 million for share buybacks (the "OLCA Waiver") – for more information on the OLCA please refer to the Annual Report 2025;

ii. a binding term sheet granting us licenses to certain intellectual property rights relating to Ouro's research programs, including Ouro's lead program of gamgertamig for development purposes, and to the BCMAxCD19xCD3 T cell engager program and other preclinical programs for development and commercialization purposes (the "Licensing Term Sheet"); and

iii. a binding term sheet pursuant to which we would acquire substantially all Ouro's operational assets in connection with the Acquisition, including facilities and personnel, such that we would obtain an operating business (the "Asset Acquisition Term Sheet").

The acquisition by Gilead was completed on June 3, 2026 and the Framework Agreement came into effect at the same date, followed by the aquisition by us on June 4, 2026.

Financial details of the Framework Agreement

Under the Framework Agreement, our share of the total consideration for the Acquisition amounts to 50% of the upfront consideration of $1.675 billion and 50% of any contingent milestone payments, which also includes the consideration under the Asset Acquisition Term Sheet.

Under the Licensing Term Sheet, we are required to fund our share of payments owed to Keymed Biosciences Chengdu Co., Ltd ("Keymed") under the head license agreement between Keymed and Ouro (the "Keymed Agreement"), comprising 25% of the milestone payments and 50% of the royalty payments that become due to Keymed with respect to gamgertamig products. Based on Ouro's original transaction with Keymed, Keymed owns the right to develop the program in Greater China and is entitled to total development and commercial milestones of up to $610 million and tiered royalties of 7% – 14% on net sales of gamgertamig.

We will also bear all costs of development prior to registrational studies for gamgertamig pursuant to agreed-upon research plans and budgets, including Ouro's current clinical trials, while costs of registration-enabling clinical development would be shared equally between the parties, with execution leadership divided by indication.

We are eligible for up to $100 million in milestone payments upon Gilead's initiation of the first registrational trials for gamgertamig in certain other indications.

Gilead will be responsible for commercialization, including all related costs, globally outside of Keymed's territories. Upon commercialization, Gilead will pay us tiered royalties between 20 – 23% on net sales of gamgertamig.

In addition, we in-licensed a preclinical portfolio of three additional autoimmune focused programs originally from Ouro, on which Gilead has the option to opt into a 50/50 profit split post clinical proof-of-concept for $75 million per program.

The OLCA Waiver allows us to spend $500 million of cash (and any additional cash generated from that amount) to acquire or develop research programs independently from Gilead and not subject to Gilead's rights under the OLCA. In addition, we can elect to use up to $150 million of that $500 million for potential share repurchases, dividend payments and other distributions of our capital stock, subject to certain limitations.

Acquisition of Ouro Medicines Inc.

On June 4, 2026, through our acquisition of 100% of the shares of Ouro Medicines Inc. renamed as Lakefront Biotherapeutics West LLC, we have acquired substantially all of Ouro Medicines' team including 25 FTEs and operational assets in connection with Gilead's acquisition of Ouro Medicines and will collaborate with Gilead on the development of gamgertamig (an investigational BCMAxCD3 bispecific T-cell engager for the treatment of autoantibodies driven immune-mediated disease).

The main reason for this acquisition is to invest in differentiated science and accelerate the development of therapies that address significant unmet need. Combined with existing expertise in immunology and cell therapy, this approach supports our ambition to shift treatment paradigms from chronic disease management toward the potential for durable immune reset.

The acquisition of Ouro Medicines Inc. (now renamed Lakefront Biotherapeutics West LLC) is further described in the notes to our interim consolidated financial statements.

Conversion of convertible loan to Coultreon Biopharma BV into shares

In April 2025, we participated in Onco3R's start-up capital via a convertible loan facility of €20 million, which would convert during the next equity financing round. Onco3R Therapeutics BV was renamed to Coultreon Biopharma BV ("Coultreon"). This convertible loan facility was presented in the line "Convertible loan" in our **statement of financial position** and was measured at fair value through profit or loss.

In April 2026, Coultreon announced the closing of an oversubscribed $125 million Series A financing round. The financing will support the clinical development of Coultreon's lead immunology program, COL-5671 (formerly O3R-5671), a highly selective SIK3 inhibitor in Phase 1, with potential to demonstrate clinical proof-of-concept in 2027. COL-5671 was initially developed by Lakefront and ownership was fully transferred to Coultreon in April 2025, when Lakefront provided seed financing to the company with a convertible note investment that converted into equity ownership in Coultreon in

connection with Series A financing. As of June 30, 2026, Lakefront holds 29.12% of Coultreon's currently issued and outstanding shares.

Share Repurchase Program

At the Extraordinary Shareholder Meeting held on April 28, 2026 (the "2026 EGM"), it was resolved to authorize the Board of Directors, without prior authorization of the Shareholders' Meeting, in accordance with Belgian law and within the limits provided, to acquire a maximum of ten per cent (10%) of the number of shares existing at the end of the 2026 EGM, for a consideration equivalent to the closing price of Lakefront's share on Euronext Brussels, on the day immediately preceding the acquisition, plus a maximum of fifteen percent (15%) or minus a maximum of fifteen percent (15%). This authorization is valid for five years from the date of the publication in the Annexes to the Belgian State Gazette of the minutes of the 2026 EGM.

On June 9, 2026, we announced the launch of a share repurchase program (the "Program"), under which we may repurchase ordinary shares for an aggregate amount of up to €50 million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into via a discretionary mandate with Morgan Stanley & Co International PLC.

As of June 30, 2026, we were holding 241,904 of our own ordinary shares, for a total purchase value of €6,078,112.05 at an average price of €25.13 per share (of which €2,869,971.03 was paid in cash and €3,208,141.02 still to be paid on June 30, 2026). The outstanding amount (unpaid) represents a financial liability that was presented as part of the trade and other liabilities line in our consolidated statement of financial position. The purchase value is disclosed on the line "Own shares" in our consolidated statement of changes in equity.

Critical Accounting Judgements and Key Sources of Estimation Uncertainty

There were no significant changes in our critical accounting judgements and key sources of estimations uncertainty compared to those used in the most recent annual consolidated financial statements of December 31, 2025, except for the following new critical accounting judgements and key sources of estimation uncertainty.

Key sources of estimation

Determination of fair value of convertible loan receivable

As there is no active market for the convertible loan and no reference share value is readily available of Coultreon, which is a very early-stage R&D organization at the moment, we establish the fair value by using other valuation techniques. The fair value has been determined mainly by reference to the initial transaction price and adjusted as necessary for impairment and revaluations with reference to capitalized interests, relevant available information and recent financing rounds.

The convertible loan receivable was converted into equity ownership in Coultreon in connection with Series A financing in April 2026. As a result, the convertible loan receivable was reclassified to an equity instrument held at fair value through other comprehensive income. The fair value of equity instruments is estimated by management based on the cost of investment and adjusted as necessary for impairment and revaluations with reference to relevant available information and recent financing rounds. The inputs are categorized as Level 3 inputs. We refer to our **Annual Report 2025** for more detailed information.

Critical accounting judgements

Equity investment – Coultreon

Our convertible loan receivable in Coultreon was converted into 29.12% of current equity ownership in Coultreon following the successful completion of Coultreon's Series A Financing round. Although after conversion of the convertible loan, we hold 29.12% of currently issued and outstanding shares and corresponding voting rights, we concluded significant influence not to exist as we do not have representation on the Board of Directors, only holding a non-voting observer position, and we do not have substantive rights to participate in financial and operating policy decisions under the current shareholder agreement. Accordingly, the investment is accounted for as an equity instrument measured at fair value through other comprehensive income in accordance with IFRS 9 rather than as an investment in an associate under IAS 28.

Details of the Unaudited Condensed Consolidated Interim Results

Collaboration revenues

The following table summarizes our collaboration revenues for the six months ended June 30, 2026 and 2025:

			Six months ended June 30	
(thousands of €)	Over time	Point in time	**2026**	2025
Recognition of non-refundable upfront payments and license fees			**–**	**116,226**
Gilead collaboration agreement for drug discovery platform	✓		–	115,046
Cartilla Therapeutics GLPG1972		✓	–	1,180
Royalties			**4,542**	**5,553**
Gilead royalties on Jyseleca®		✓	4,542	5,553
Total collaboration revenues			**4,542**	**121,779**

Operating costs and other operating income

Operating costs

Research and development expenditure

The following table summarizes our research and development expenditure for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Personnel costs	(24,856)	(82,282)
Subcontracting	(25,227)	(141,001)
Disposables and lab fees and premises costs	(1,056)	(6,575)
Amortization, depreciation and impairment	(1,597)	(32,232)
Professional fees	(639)	(5,693)
Other operating expenses	(3,111)	(10,244)
Total research and development expenses	**(56,486)**	**(278,027)**

The decrease in research and development expenses was primarily attributable to the strategic reorganization and the wind-down of the cell therapy activities in 2025. As a result, the comparative period included significant non-recurring expenses that were absent or substantially lower in the current period, principally:

- subcontracting costs related wind-down of the cell therapy and small molecule programs, including expenses associated with the early termination of collaboration agreements;
- severance costs included in personnel expenses; and
- impairment, amortization and depreciation charges relating to fixed assets associated with the discontinued small molecule programs and wind down of the cell therapy activities.

The table below summarizes our R&D expenditure for the six months ended June 30, 2026 and 2025, broken down by program.

	Six months ended June 30	
(thousands of €)	**2026**	2025
SIKi program	(85)	(9,054)
TYK2 program on GLPG3667	(11,674)	(16,306)
Cell therapy programs in oncology	(38,754)	(115,978)
Gamgertamig	(1,190)	–
Other discovery programs	(4,783)	(136,689)
Total research and development expenses	**(56,486)**	**(278,027)**

The research and development expenses decreased in the first half of 2026 compared to the same period last year, primarily due to the strategic reorganization and the wind-down of the cell therapy activities in 2025, which resulted in a decrease of expenses for the different existing programs.

Sales and marketing expenses

The following table summarizes our sales and marketing expenses for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Personnel costs	(2,931)	(4,061)
Amortization, depreciation and impairment	(11)	3,755
External outsourcing costs	(2,676)	(520)
Professional fees	–	(93)
Other operating expenses	(208)	(637)
Total sales and marketing expenses	**(5,826)**	**(1,556)**

General and administrative expenses

The following table summarizes our general and administrative expenses for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Personnel costs	(26,941)	(37,126)
Amortization, depreciation and impairment	(1,432)	(4,044)
Legal and professional fees	(10,464)	(20,794)
Other operating expenses	(13,347)	(10,950)
Total general and administrative expenses	**(52,184)**	**(72,914)**

Personnel costs decreased due to severance accruals recorded in the first half of 2025. Legal and professional fees should be considered together with other operating expenses, the total of both decreased due to one-off professional fees linked to the small molecules restructuring recorded in the first half of 2025.

Other operating income

The following table summarizes our other operating income for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Grant income	–	57
R&D incentives income	2,314	11,946
Other	321	2,929
Total other operating income	**2,635**	**14,932**

Lower R&D incentives as a result of the strategic reorganization and wind down of the cell therapy activities explain the decrease in other operating income.

Financial income/expenses

The following table summarizes our financial income/expenses (–) for the six months ended June 30, 2026 and 2025:

	Six months ended June 30	
(thousands of €)	**2026**	2025
Fair value adjustments and net currency exchange differences:		
Net unrealized currency exchange gain/loss (–)	40,563	(38,430)
Net realized currency exchange loss	(204)	(945)
Fair value gain on financial assets held at fair value	4,311	347
Gain from settlement of hedging instrument	–	22,745
Fair value gain/loss (–) on current financial investments	52,449	(49,945)
Total fair value adjustments and net currency exchange differences	**97,119**	**(66,228)**
Other financial income:		
Interest income	25,010	21,791
Discounting effect of non-current R&D incentives receivables	1,284	727
Other finance income	185	18
Total other financial income	**26,479**	**22,536**
Other financial expenses:		
Interest expenses	(127)	(304)
Discounting effect of other non-current liabilities	–	(661)
Other finance charges	(287)	(399)
Total other financial expenses	**(414)**	**(1,364)**
Total net financial result	**123,183**	**(45,056)**

Fair value adjustments and net currency differences increased due to the evolution of the USD exchange rate.

Discontinued operations

The following disclosure illustrates the result from our discontinued operations, related to the transfer of the Jyseleca® business to Alfasigma on January 31, 2024.

1.1 Net cash inflow on disposal of the Jyseleca® business

	Six months ended June 30	Six months ended June 30
(thousands of €)	**2026**	**2025**
Release from escrow account	–	18,323
Contribution for R&D costs paid by us to Alfasigma	–	25,000
Earn-outs paid by Alfasigma	4,205	4,217
Cash in/cash out (-) from the disposal of subsidiaries, net of cash disposed of	**4,205**	**(2,459)**

1.2 Result from discontinued operations

(thousands of €, except per share data)	Six months ended June 30 2026	2025
Research and development expenses	220	(12,516)
Sales and marketing expenses	–	(588)
General and administrative expenses	(47)	(32)
Other operating income	129	11,599
Operating profit/loss (–)	**302**	**(1,537)**
Other financial income	1,026	1,921
Profit before tax	**1,328**	**384**
Income taxes	(557)	(532)
Net profit/loss (–)	**771**	**(148)**
Basic and diluted earnings/loss (–) per share from discontinued operations	**0.01**	**0.00**
Weighted average number of shares – Basic (in thousands of shares)	65,885	65,897
Weighted average number of shares – Diluted (in thousands of shares)	65,954	65,897

For the six months ending June 30, 2025, the R&D expenses related to the settlement of disputed expenses with Alfasigma.

Other operating income for the first six months of 2025, included a fair value adjustment of the contingent consideration receivable from Alfasigma as a consequence of an adjusted sales forecast.

Other financial income contains discounting components on the contingent consideration receivables.

1.3 Cash flow from discontinued operations

(thousands of €)	Six months ended June 30 2026	2025
Net cash flow used in operating activities	(384)	(555)
Net cash flow generated from/used (–) in investing activities	4,205	(2,459)
Net cash flow generated from/used in (–) discontinued operations	**3,821**	**(3,014)**

Net Asset acquisition – Ouro Medicines

On June 4, 2026, Gilead acquired all the outstanding equity of Ouro Medicines for $1,675 million and up to $500 million in contingent milestone payments. We and Gilead will equally split the upfront payment, subject to customary adjustments, and contingent milestone payments of up to $500 million.

On June 4, 2026, through our acquisition of 100% of the shares of Ouro Medicines, we have acquired substantially all of Ouro Medicines' team including 25 FTEs and operational assets and assumed transferred liabilities in connection with Gilead's acquisition of Ouro Medicines and we will collaborate with Gilead on the development of gamgertamig. Gamgertamig is an investigational BCMAxCD3 bispecific T-cell engager for the treatment of autoantibodies driven immune-mediated disease. Gamgertamig is in-licensed from Keymed Biosciences, which owns the rights to develop the program in Greater China.

By applying the optional concentration test as described under IFRS 3 Business Combinations, 98.0% of the fair value of the gross assets acquired is concentrated in the OM336 compound. As substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the acquisition of Ouro Medicines does not represent the acquisition of a business but rather the acquisition of net assets.

The cost of the acquisition (the upfront payment and $16.3 million of direct acquisition costs) is to be allocated to the individual identifiable assets and liabilities based on their relative fair values at the date of acquisition. We applied an approach whereby any identifiable asset or liability initially measured at an amount other than costs, is initially measured at the amount specified in the IFRS Accounting Standard. We deducted from the cost of the acquisition the amounts allocated to the assets and liabilities initially measured at an amount other than cost, and then allocated the residual transaction price to the remaining identifiable assets and liabilities based on their relative fair values at the date of acquisition.

This approach resulted in the following net assets recognized at acquisition date (based on the initial recognition exemption in IAS 12 Income Taxes, no deferred tax liabilities were recognized):

	June 4, 2026
	OURO Medicines
(thousands of €)	At cost
Intangible assets	734,165
Property, plant and equipment	510
Other non-current assets	41
Trade and other receivables	3,020
Cash and cash equivalents	19,132
Other current assets	48
Non-current lease liabilities	(190)
Current lease liabilities	(174)
Trade and other liabilities	(3,565)
Net assets acquired	**752,986**
Net cash outflow arising on acquisition	
Consideration paid in cash	743,255
Transaction costs paid in cash	9,398
Less: cash and cash equivalents balances acquired	(19,132)
Cash out from the acquisition of subsidiaries, net of cash acquired	**733,521**

In the absence of any guidance in IFRS Accounting Standards regarding the accounting for variable payments for the purchase of net assets which is not part of a business combination, we developed an accounting policy whereby the variable consideration (the "Contingent Consideration") is only recognized as a liability when the condition that triggers the obligation is met. Therefore, each of the contingent milestone payments of up to $250 million (50% of $500 million that shall be paid by us, other 50% by Gilead) will be recognized when the milestone events have been reached. As these milestone events all relate to the further development of OM336, these milestones when recognized, will be added to the cost of the OM 336 compound being recognized.

The Contingent Consideration totals up to a maximum amount of $500 million (50% to be paid from our side) consisting of clinical development milestones up to a maximum amount of $200 million (50% to be paid from our side) and regulatory milestones up to a maximum amount of $300 million (50% to be paid from our side).

Cash position

Cash and cash equivalents and financial investments totaled €2,239.5 million on June 30, 2026 (€2,998.0 million on December 31, 2025).

Cash and cash equivalents and financial investments comprised cash at banks, term deposits, and money market funds. Our cash management strategy monitors and optimizes our liquidity position. Our cash management strategy allows short-term deposits with an original maturity exceeding three months while monitoring all liquidity aspects.

All cash and cash equivalents are available upon maximum three months' notice period and without significant penalty. Cash at banks were mainly composed of current accounts. Our credit risk is mitigated by selecting a panel of highly rated financial institutions for our deposits.

Current financial investments comprised €1,058.8 million of term deposits which all had an original maturity longer than three months and which are not available on demand within three months. Our current financial investments also comprised of money market funds. Our money market funds portfolio consists of AAA short-term money market funds with a diversified and highly rated underlying portfolio managed by established fund management companies with a proven track record.

	June 30	December 31
(thousands of €)	**2026**	2025
Money market funds	1,044,811	1,472,031
Term deposits	1,058,786	1,438,149
Total current financial investments	**2,103,597**	**2,910,180**
Cash at banks	135,952	87,868
Total cash and cash equivalents	**135,952**	**87,868**

On June 30, 2026, our cash and cash equivalents and current financial investments included $1,962.2 million held in U.S. dollars ($2,159.0 million on December 31, 2025) which could generate foreign exchange gains or losses in our financial results in accordance with the fluctuation of the EUR/U.S. dollar exchange rate as our functional currency is EUR. The foreign exchange loss (–)/gain in case of a 10% change in the EUR/U.S. dollar exchange rate amounts to €172.2 million.

Note to the cash flow statement

(thousands of €)	June 30 2026	2025
Adjustment for other non-cash transactions		
Amortization, depreciation and impairment on intangible assets and property, plant and equipment	3,040	36,515
Share-based compensation expenses	6,780	12,661
Decrease in retirement benefit obligations	–	(1)
Unrealized exchange losses/gains (–) and non-cash other financial result	(43,139)	37,707
Discounting effect of other non-current liabilities	–	661
Discounting effect of contingent consideration receivable	(1,026)	(1,921)
Net change in fair value of current financial investments	(45,964)	67,439
Fair value adjustment financial assets held at fair value through profit or loss	(4,311)	(347)
Fair value adjustment contingent consideration receivable	(129)	(11,579)
Impairment loss reversal on trade receivables	–	(9,643)
Other non-cash expenses	–	(155)
Total adjustment for non-cash transactions	**(84,749)**	**131,337**
Adjustment for items to disclose separately under operating cash flow		
Interest expense	127	304
Interest income	(25,010)	(21,791)
Income taxes	697	(1,256)
Total adjustment for items to disclose separately under operating cash flow	**(24,186)**	**(22,743)**
Adjustment for items to disclose under investing and financing cash flows		
Gain on sale of subsidiaries	–	(1,085)
Proceeds from settlement of hedging instrument	–	(22,745)
Investment income on financial investments	(6,484)	(17,498)
Total adjustment for items to disclose separately under investing and financing cash flow	**(6,484)**	**(41,328)**
Change in working capital other than deferred income		
Decrease in inventories	13,948	17,553
Decrease in receivables	36,236	44,842
Increase/decrease (–) in liabilities	(49,048)	49,940
Total change in working capital other than deferred income	**1,136**	**112,335**

Provisions

(thousands of €)	Provisions Restructuring small molecules programs	Restructuring cell therapy activities	**Total provisions**
On January 1, 2026	**29,175**	**16,324**	**45,499**
Unused amount reversed	(529)	(7,227)	**(7,756)**
Amounts settled	(28,646)	(7,240)	**(35,886)**
Other movements	–	(455)	**(455)**
On June 30, 2026	**–**	**1,402**	**1,402**

The decrease in the provisions primarily reflected cash payments relating to early termination of collaboration agreements as a result of the discontinuation of the small molecules activities and as a result of the wind-down of the cell therapy activities. In addition, €7.2 million of the provision was reversed following the completion of negotiations with suppliers and the reassessment of expected costs, which resulted in lower settlement amounts than originally estimated. No significant new restructuring provisions were recognized during the period. The remaining provision is expected to be substantially utilized during the second half of 2026.

Financial risk management

The following table summarizes the categories of financial assets and liabilities held at fair value:

(thousands of €)	Fair value hierarchy	June 30 **2026**	December 31 2025
Financial assets held at fair value through other comprehensive income			
Equity investments	Level 3	73,857	46,809
Financial assets held at fair value through profit or loss			
Contingent consideration receivable	Level 3	52,095	54,705
Financial investments	Level 1	1,044,811	1,472,031
Convertible loan	Level 3	62	21,175

The increase of the fair value of the equity investments is due to the conversion of the loan to Coultreon into equity and to an exchange gain of €1.5 million; the latter is reflected in the other reserves (other comprehensive income) in the consolidated equity. The valuation of all our equity investments is based on Level 3 assumptions as it includes investments in non-quoted companies. These investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Subsequent valuation is based on internal and external evidence such as information from recent financing rounds, scientific updates and other valuation techniques.

The contingent consideration receivable relates to fair value of the future earn-outs to be obtained from Alfasigma for the sale of Jyseleca®. €7.8 million is presented on the line “Trade and other receivables” and €44.4 million is presented on the line “non-current contingent consideration receivable”. The total potential amount consists of sales-based milestone payments totaling €120 million and mid-single to mid-double-digit royalties on European sales. The valuation is based on Level 3 assumptions based on our best estimate of the expected earn-outs and sales milestones in the future, considering probability adjusted sales forecasts of Jyseleca® discounted using an appropriate discount rate. The fair value is reviewed at each reporting date and any changes are reflected in our consolidated income statement, in the line ‘Net profit/loss (–) from discontinued operations, net of tax’. A change in expected sales by +15% would result in an increase of €14.3 million in the total contingent consideration receivable on June 30, 2026. A change in expected sales by –15% would result in a decrease of €13.9 million in the total contingent consideration receivable on June 30, 2026.

We refer to **critical accounting judgements and key sources of estimation uncertainty** for details about the fair value of the convertible loan.

Off-balance Sheet Arrangements

Contractual obligations and commitments

We have certain purchase commitments principally with CRO subcontractors and certain collaboration partners.

On June 30, 2026, we had outstanding obligations for purchase commitments, which become due as follows:

(thousands of €)	Total	Less than 1 year	1 – 3 years	3 – 5 years	More than 5 years
Purchase commitments	**81,952**	**60,995**	**13,810**	**2,539**	**4,608**

Our purchase commitments at the end of June 2026 included €55.4 million related to projects in development phase, €1.1 million for projects in discovery research phase, €24.5 million for shared services, and €1.0 million for supply chain, commercial and medical affairs.

We refer to our **Annual Report 2025** for additional information on our contingent contractual obligations.

Related Party Transactions

Key management personnel

On March 6, 2026, the members of the Executive Committee were offered new subscription rights under the Subscription Right Plan 2026, which have all been accepted in full. The subscription rights have an exercise term of eight years as of the date of the notarial deed enacting the acceptance of the subscription rights. The exercise price of the subscription rights is €28.82 (the closing price of the Lakefront share on Euronext Brussels and Amsterdam on the date preceding the offer). Each subscription right gives the right to subscribe for one new Lakefront share. The subscription rights are subject to a 3-year cliff vesting schedule and can in principle not be exercised prior to March 6, 2029.

On March 6, 2026, the members of the Executive Committee were offered new restricted stock units ("RSUs") under the Lakefront 2026 Restricted Stock Units/Long-Term Incentive Plan ("2026 RSU LTIP Plan"). The RSUs were offered for no consideration. Each RSU represents the right to receive, at Lakefront's discretion, one Lakefront share or a payment in cash of an amount equivalent to the volume-weighted average price of the Lakefront share on Euronext Brussels over the 30-calendar day period preceding the relevant vesting date. The RSUs granted under the 2026 RSU LTIP Plan are subject to a 4-year phased vesting schedule, whereby 25% of the RSUs granted will vest on each anniversary date of the date of the grant.

On March 6, 2026, the members of the Executive Committee were offered new performance stock units ("PSUs") under the Lakefront 2026 Performance Stock Units/Long-Term Incentive Plan ("2026 PSU LTIP Plan"). The PSUs were offered for no consideration, but the vesting of the PSUs is subject to meeting certain performance criteria as determined in the 2026 PSU LTIP Plan. Each PSU represents the right to receive, at Lakefront's discretion, one Lakefront share or a payment in cash of an amount equivalent to the volume-weighted average price of the Lakefront share on Euronext Brussels over the 30-calendar day period preceding the relevant vesting date. The PSUs granted under the 2026 PSU LTIP Plan are subject to a 3-year cliff vesting schedule in a range from 0% to 150% and can in principle not vest prior to March 6, 2029.

On April 28, 2026, we held our Annual Shareholders' Meeting ("AGM"). The AGM approved the appointment of Mr. Henry Gosebruch as Executive Director for an additional period of four years, the appointment of Dr. Jane Griffiths as independent non-executive director for an additional period of four years, the appointment of Ms. Dawn Svoronos as independent non-executive director for an additional period of four years, the appointment of Dr. Neil Johnston as independent non-executive director for an additional period of two years, the appointment of Mr. Devang Bhuva as non-executive director for an additional period of three years, the appointment of Dr. Paulo Fontoura as independent non-

executive director for an additional period of three years, the appointment of Mr. Gino Santini as independent non-executive director for an additional period of four years. Mr. Gino Santini was also appointed as the new Chair of the Board of Directors.

The table below sets forth the number of subscription rights offered and accepted under Subscription Right Plan 2026, the number of RSUs and PSUs offered to each member of the Executive Committee during the first six months of 2026:

Name	Title	Number of Offered and Accepted Subscription Rights 2026	Number of Offered and Accepted RSUs 2026	Number of Offered and Accepted PSUs 2026
Henry Gosebruch	CEO	353,700	70,700	70,700
Aaron Cox	Chief Financial Officer	124,400	24,900	24,900
Fred Blakeslee	General Counsel	108,800	21,800	21,800

During the first six months of 2026, other than as disclosed in the paragraph above there were no changes to related party transactions disclosed in the 2025 annual report that potentially had a material impact on our financials of the first six months of 2026.

Events after the End of the Reporting Period

There were no adjusting events nor material non-adjusting events to be reported.

Approval of Interim Financial Statements

The interim financial statements were approved by the Board of Directors on August 5, 2026.